Larimar Therapeutics (LRMR) Total Debt Growth (3y) (2017 - 2020)
Powered by 
Analysis
Larimar Therapeutics (LRMR) Total Debt Growth (3y) (2017 - 2020) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -0.51% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -0.71% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 0.08% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 8.78% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -22.30% |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 70.33% |
| Dec 31, 2019 | 63.68% |
| Sep 30, 2019 | 59.24% |
| Jun 30, 2019 | 56.08% |
| Mar 31, 2019 | 53.78% |
| Dec 31, 2018 | 47.83% |
| Sep 30, 2018 | 50.79% |
| Jun 30, 2018 | 28.93% |
| Mar 31, 2018 | 28.17% |
| Dec 31, 2017 | 38.32% |
| Sep 30, 2017 | -44.71% |
| Jun 30, 2017 | -34.81% |